Module 11 – Paediatric & Vulnerable Patient Considerations
Part of the Purus Lumina Device Care Education Programme
The highest-risk patients in the pathway are the ones for whom no standard exists at all.
CBPMs are prescribed in the United Kingdom across a wide range of patient groups. The majority are adults managing chronic conditions. A smaller but significant proportion are children — paediatric patients prescribed CBPMs for conditions including treatment-resistant epilepsy, where cannabis-based medicines have demonstrated clinical efficacy where other treatments have failed.
A further group are vulnerable adults — patients whose cognitive impairment, physical disability, mental health condition, or social circumstances mean they cannot independently manage their own device care. These patients depend on carers, family members, or support workers to maintain the device through which their prescription is administered.
Both groups represent the highest-risk cohort in the prescribed CBPM pathway. Both are prescribed a CBPM administered through a classified medical device. Neither group has a documented care standard written for their specific circumstances. This module is that standard.
Paediatric prescriptions
Cannabis-based medicines are prescribed to children in the UK primarily for treatment-resistant epilepsy. The most widely known cases involve children for whom conventional anti-epileptic medications have failed and for whom a cannabis-based medicine — typically a CBD-dominant preparation — has produced a clinically significant reduction in seizure frequency.
In some paediatric cases, the CBPM is administered via a prescribed dry herb device. In others, it is administered as an oil or oral preparation. Where a prescribed dry herb device is involved, it is operated entirely by a parent, guardian, or carer — the child cannot operate it independently. The care obligation falls entirely on the adult responsible for the child's medical care.
The care standard for paediatric device use: Where a prescribed dry herb device is used to administer a CBPM to a child, the care standard documented in this curriculum applies in full — and the threshold for compliance is higher, not lower. A child cannot identify a contaminated device. A child cannot report that the device tastes different, that the draw resistance has changed, or that the vapour quality is inconsistent. The adult responsible for the device is the only quality control mechanism in the pathway. The care standard is not optional in this context. It is the minimum acceptable standard for the administration of a prescription to a child.
Prescriber and clinic obligations: A clinician who prescribes a CBPM to a paediatric patient and does not provide the parent or guardian with a documented device care protocol has not fully discharged their duty of care. The informed consent process for a paediatric prescription must include information about how the device is to be maintained. No UK clinic operating within the prescribed CBPM pathway currently provides this. This curriculum documents that it should be standard practice — and that in a paediatric context, the absence of this information is a more serious gap than in any other patient group.
Vulnerable adult patients
Vulnerable adult patients in the prescribed CBPM pathway include individuals with cognitive impairment — dementia, acquired brain injury, learning disability — as well as patients with severe physical disability, patients with serious mental illness, and patients in circumstances of social vulnerability that affect their capacity to manage their own medical care.
For these patients, device care is not a task they can perform independently. It is performed by whoever is responsible for their care — a family member, a professional carer, a support worker, or a care home. In each case, the person performing the device care has received no training, no protocol, and no guidance from the clinical pathway that prescribed the CBPM.
Capacity and consent: A vulnerable adult patient who lacks capacity to consent to their own medical treatment is subject to the Mental Capacity Act 2005. Decisions about their medical care — including the administration of a prescribed CBPM — must be made in their best interests. A best interests decision that involves administering a CBPM through a contaminated device is not a decision made in the patient's best interests. The person making that decision — whether a family member, a professional carer, or a care home — has a legal obligation to ensure the device is maintained correctly. No one has told them what correctly means. This curriculum is that information.
Care homes and residential settings: Where a vulnerable adult patient resides in a care home or other residential setting, the device care obligation falls on the care home. A care home that administers a prescribed CBPM through a device it has not maintained correctly is administering a prescription incorrectly. The Care Quality Commission (CQC) regulates care homes in England. The safe administration of prescribed medication is a core CQC standard. A care home that cannot demonstrate that it maintains the device used to administer a prescribed CBPM to the standard documented in this curriculum is not meeting that standard. No CQC inspection framework currently addresses this. This curriculum submits that it should.
The specific care obligations for high-dependency patients
Where a patient cannot independently manage their device care — whether paediatric or vulnerable adult — the following obligations apply to the person responsible for their care:
- Full protocol compliance: The cleaning, drying, maintenance, and replacement schedule documented in Modules 2, 3, and 8 applies without modification.
- Pre-session inspection: Every pre-session check documented in Module 5 must be completed before every session.
- Hand hygiene without exception: The hand hygiene standard documented in Modules 2 and 10 applies to every person who handles the device, every time.
- Dedicated mouthpiece: Each patient must have their own mouthpiece. It must not be handled without gloves by any carer.
- Documentation: In a professional care setting, every session of CBPM administration should be documented in the patient's care record.
- Escalation: Where a carer identifies a problem with the device, they must not continue with the session. They must escalate to the prescribing clinic before the next administration.
The regulatory and institutional gap
The absence of a device care standard for paediatric and vulnerable adult patients is the most serious gap documented in this curriculum. The MHRA has not issued guidance. NHS England has not issued guidance. NICE has not issued guidance. The Home Office has not issued guidance. No clinic operating within the prescribed CBPM pathway in the UK has produced a protocol for paediatric or vulnerable adult device care. No care agency has a documented standard for carer-assisted CBPM administration.
This curriculum documents that gap and submits it to each of those bodies as a matter of public record. Purus Lumina is the first entity to document this gap in a structured, published, and formally submitted educational format. That is not a commercial claim. It is a matter of public record.
In plain terms
If you are a parent administering a prescribed CBPM to your child through a prescribed dry herb device, the care standard in this curriculum is not optional. Your child cannot tell you the device is contaminated. You are the only quality control in the pathway.
If you are a carer administering a prescribed CBPM to a vulnerable adult, you are handling a classified medical instrument used to administer a prescription. Wash your hands. Inspect the device. Follow the protocol. Document what you did.
No one told you this before. Now you know.
Notice of Intent
This curriculum has been submitted to the MHRA, Home Office, NHS England, NICE, the Care Quality Commission, relevant parliamentary and clinical bodies, and device manufacturers operating within the UK prescribed CBPM pathway, as a formal educational contribution to a documented gap in patient care. It is published in perpetuity as a matter of public record. Purus Lumina reserves all rights to the curriculum structure, content, and methodology.
Get the Solution
The Purus Lumina Device Purification Solution — purpose-formulated for dry herb devices used in prescribed CBPM administration. 99.9% pharmaceutical-grade. UK-made. Available in 250ml, 500ml, and 1L.
Get the Device Purification Solution →
Continue to Module 12 – The Patient Record →
← Back to Module 10 – Shared Device Risk
← Return to the Device Care Education hub
Module 11 is part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. Published as a matter of public record. Preserved in perpetuity.
This module was published on 4 July 2026 and exists in perpetuity as part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. It will not be removed.
Glenn Hailes · Director · Purus Lumina Ltd · 3rd Floor, 86–90 Paul Street · London EC2A 4NE · United Kingdom · Registered in England and Wales